Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13G/A for ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO).
- Disclosed ownership: 8.5%.
- Date of event: 30 Jun 2025.
Redmile Group, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO)
- Filing Manager
- Redmile Group, LLC
- Reporting Manager
- Redmile Group, LLC
- Symbol
- ALXO
- Shares outstanding
- 54,605,353 shares
- Disclosed Ownership
- 4,641,455 shares
- Ownership
- 8.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:17:11 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Redmile Group, LLC disclosed 8.5% ownership in ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 16:17.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 8.5% | 4,641,455 | 0 | 4,641,455 | /s/ Jeremy C. Green | Managing Member | |
| Jeremy C. Green | 8.5% | 4,641,455 | 0 | 4,641,455 | /s/ Jeremy C. Green | Jeremy C. Green | |
| Redmile Biopharma Investments III, L.P. | 6.7% | 3,675,481 | 0 | 3,675,481 | /s/ Jeremy C. Green | Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P. |